Baseline Electrocardiographic and Echocardiographic Assessment May Help Predict Survival in Lung Cancer Patients-A Prospective Cardio-Oncology Study
- PMID: 35454916
- PMCID: PMC9032028
- DOI: 10.3390/cancers14082010
Baseline Electrocardiographic and Echocardiographic Assessment May Help Predict Survival in Lung Cancer Patients-A Prospective Cardio-Oncology Study
Abstract
Cardiovascular disease and cancer coexist and lead to exertional dyspnea. The aim of the study was to determine the prognostic significance of cardiac comorbidities, ECG and baseline echocardiography in lung cancer patients with varying degrees of reduced performance status. This prospective study included 104 patients with histopathologically confirmed lung cancer, pre-qualified for systemic treatment due to metastatic or locally advanced malignancy but not eligible for thoracic surgery. The patients underwent a comprehensive cardio-oncological evaluation. Overall survival negative predictors included low ECOG 2 (Eastern Cooperative Oncology Group) performance status, stage IV (bone or liver/adrenal metastases in particular), pleural effusion, the use of analgesics and among cardiac factors, two ECG parameters: atrial fibrillation (HR = 2.39) and heart rate >90/min (HR = 1.67). Among echocardiographic parameters, RVSP > 39 mmHg was a negative predictor (HR = 2.01), while RVSP < 21 mmHg and RV free wall strain < −30% were positive predictors (HR = 0.36 and HR = 0.56, respectively), whereas RV GLS < −25.5% had a borderline significance (HR = 0.59; p = 0.05). Logistical regression analysis showed ECOG = 2 significantly correlated with the following echocardiographic parameters: increasing RVSP, RV GLS, RV free wall strain and decreasing ACT, FAC (p < 0.05). Selected echocardiographic parameters may be helpful in predicting poor performance in lung cancer patients and, supplemented with ECG evaluation, broaden the possibilities of prognostic evaluation.
Keywords: ECG; atrial fibrillation; cardio-oncology; cardiovascular comorbidities; echocardiography; lung cancer; performance status; prognosis; strain rate; survival.
Conflict of interest statement
S.M. declares no conflict of interest to this study. S.S. declares speaker fees: Angelini, Amgen, Astra-Zeneca, Bayer, BMS, Gilead, Pfizer, TEVA (all outside of this study).
Figures
References
-
- De Boer R.A., Hulot J.S., Tocchetti C.G., Aboumsallem J.P., Ameri P., Anker S.D., Bauersachs J., Bertero E., Coats A.J.S., Čelutkienė J., et al. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) Eur. J. Heart Fail. 2020;22:2272–2289. - PMC - PubMed
-
- Cuomo A., Paudice F., D’Angelo G., Perrotta G., Carannante A., Attanasio U., Iengo M., Fiore F., Tocchetti C.G., Mercurio V., et al. New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management. Curr. Heart Fail. Rep. 2021;18:191–199. doi: 10.1007/s11897-021-00517-y. - DOI - PMC - PubMed
-
- Cuomo A., Pirozzi F., Attanasio U., Franco R., Elia F., De Rosa E., Russo M., Ghigo A., Ameri P., Tocchetti C.G., et al. Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications. Curr. Oncol. Rep. 2020;23:7. doi: 10.1007/s11912-020-00990-z. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous